An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
NCT ID: NCT00162227
Last Updated: 2014-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
2000-09-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada
NCT00162188
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
NCT00364793
Pediatric Expanded Access Program-Oral Solution (0831-908)
NCT00543530
Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
NCT00802802
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
NCT00002227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Efavirenz
Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anti-retroviral naive or experienced
* Failing or intolerant to current Anti-retroviral regimen
* Limited available viable therapeutic options
* Inability to take capsules/tablets
Exclusion Criteria
* Failure on or concomitant use of other NNRTIs
* An active AIDS-defining opportunistic infection or disease
* More than two episodes of moderate to severe diarrhea or vomiting lasting more than four days within the past three months
3 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Phoenix, Arizona, United States
Lac & Usc Medical Center
Los Angeles, California, United States
Local Institution
Washington D.C., District of Columbia, United States
Children'S Diagnostic Treatment Center
Fort Lauderdale, Florida, United States
Arnold Palmer Hospital For Children And Woman
Orlando, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
The Children'S Memorial Hospital
Chicago, Illinois, United States
University Of Chicago
Chicago, Illinois, United States
Lsu Health Sciences Center
New Orleans, Louisiana, United States
Children'S Hospital
Boston, Massachusetts, United States
University Of Massachusetts Medical School
Worcester, Massachusetts, United States
The Wellness Center
Las Vegas, Nevada, United States
Umdnj - New Jersey Medical School
Newark, New Jersey, United States
Schneider'S Childrens Hospital
New Hyde Park, New York, United States
Office Of John Montana
New York, New York, United States
St Luke'S-Roosevelt Hospital Center
New York, New York, United States
Women And Childrens Care Center
New York, New York, United States
Harlem Hospital Center
New York, New York, United States
State University Of New York At Stony Brook
Stony Brook, New York, United States
Suny Upstate Medical University
Syracuse, New York, United States
Bronx Municipal Hospital Center
The Bronx, New York, United States
Montefiore Medical Center/Aecom
The Bronx, New York, United States
New York Medical College
Valhalla, New York, United States
Metro Health Medical Center
Cleveland, Ohio, United States
Local Institution
Youngstown, Ohio, United States
St Jude Children'S Research Hospital
Memphis, Tennessee, United States
Local Institution
Houston, Texas, United States
Local Institution
Arecibo, , Puerto Rico
Local Institution
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI266-913
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.